Stem cell in the rough repair quotient mined out of a bone marrow niche

Circulation Research

Volumn 115, Issue 10, 2014, Pages 814-816

  Behfar, Atta ^a   Terzic, Andre ^a  

^a MAYO CLINIC   (United States)

Author keywords

Clinical trial; heart failure; Myocardial infarction; Regeneration; Stem cells

Indexed keywords

ACUTE HEART INFARCTION; BONE MARROW CELL; BONE MARROW DERIVED MONONUCLEAR CELL; EDITORIAL; FLOW CYTOMETRY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; ISCHEMIC CARDIOMYOPATHY; ISCHEMIC HEART DISEASE; MULTICENTER STUDY (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEM CELL NICHE; STEM CELL TRANSPLANTATION; BLOOD; CFU COUNTING; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; MALE; METABOLISM; PROCEDURES;

CD11B ANTIGEN; CD34 ANTIGEN; ITGAM PROTEIN, HUMAN;

ANTIGENS, CD11B; ANTIGENS, CD34; BONE MARROW CELLS; COLONY-FORMING UNITS ASSAY; FEMALE; HUMANS; MALE; MYOCARDIAL ISCHEMIA; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84922609188     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.114.305075     Document Type: Editorial

References (26)

1. Bailey AM, Mendicino M, Au P. An FDA perspective on preclinical development of cell-based regenerative medicine products. Nat Biotechnol. 2014;32:721-723.
2. Behfar A, Crespo-Diaz R, Terzic A, Gersh BJ. Cell therapy for cardiac repair-lessons from clinical trials. Nat Rev Cardiol. 2014;11:232-246.
3. Bartunek J, Vanderheyden M, Hill J, Terzic A. Cells as biologics for cardiac repair in ischaemic heart failure. Heart. 2010;96:792-800.
4. Telukuntla KS, Suncion VY, Schulman IH, Hare JM. The advancing feld of cell-based therapy: insights and lessons from clinical trials. J Am Heart Assoc. 2013;2:e000338.
5. Sanganalmath SK, Bolli R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res. 2013;113:810-834.
6. de Jong R, Houtgraaf JH, Samiei S, Boersma E, Duckers HJ. Intracoronary stem cell infusion after acute myocardial infarction: a meta-analysis and update on clinical trials. Circ Cardiovasc Interv. 2014;7:156-167.
7. Fisher SA, Brunskill SJ, Doree C, Mathur A, Taggart DP, Martin-Rendon E. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database Syst Rev. 2014;4:CD007888.
8. Terzic A, Behfar A. Regenerative heart failure therapy headed for optimization. Eur Heart J. 2014;35:1231-1234.
9. Cogle CR, Wise E, Meacham AM, et al; for the Cardiovascular Cell Therapy Research Network (CCTRN). Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes. Circ Res. 2014;115:867-874.
10. Simari RD, Pepine CJ, Traverse JH, et al. Bone marrow mono-nuclear cell therapy for acute myocardial infarction: a perspective from the Cardiovascular Cell Therapy Research Network. Circ Res. 2014;114:1564-1568.
11. Traverse JH, Henry TD, Pepine CJ, et al; Cardiovascular Cell Therapy Research Network (CCTRN). Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA. 2012;308:2380-2389.
12. Traverse JH, Henry TD, Ellis SG, et al; Cardiovascular Cell Therapy ResearchNetwork. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA. 2011;306:2110-2119.
13. Perin EC, Willerson JT, Pepine CJ, et al; Cardiovascular Cell Therapy Research Network (CCTRN). Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA. 2012;307:1717-1726.
14. Wollert KC, Meyer GP, Lotz J, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004;364:141-148.
15. Schächinger V, Erbs S, Elsässer A, et al; for the REPAIR-AMI Investigators. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006;355:1210-1221.
16. Losordo DW, Henry TD, Davidson C, et al; ACT34-CMI Investigators. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011;109:428-436.
17. Poglajen G, Sever M, Cukjati M, Cernelc P, Knezevic I, Zemljic G, Haddad F, Wu JC, Vrtovec B. Effects of transendocardial CD34+ cell transplantation in patients with ischemic cardiomyopathy. Circ Cardiovasc Interv. 2014;7:552-559.
18. Behfar A, Yamada S, Crespo-Diaz R, Nesbitt JJ, Rowe LA, Perez-Terzic C, Gaussin V, Homsy C, Bartunek J, Terzic A. Guided car-diopoiesis enhances therapeutic beneft of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J Am Coll Cardiol. 2010;56:721-734.
19. Marbán E, Malliaras K. Boot camp for mesenchymal stem cells. J Am Coll Cardiol. 2010;56:735-737.
20. Lane SW, Williams DA, Watt FM. Modulating the stem cell niche for tissue regeneration. Nat Biotechnol. 2014;32:795-803.
21. Bartunek J, Behfar A, Dolatabadi D, et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specifed bio-logics. J Am Coll Cardiol. 2013;61:2329-2338.
22. Behfar A, Terzic A. Derivation of a cardiopoietic population from human mesenchymal stem cells yields cardiac progeny. Nat Clin Pract Cardiovasc Med. 2006;3(suppl 1):S78-S82.
23. Sheridan C. Cardiac stem cell therapies inch toward clinical litmus test. Nat Biotechnol. 2013;31:5-6.
24. Dimmeler S, Ding S, Rando TA, Trounson A. Translational strategies and challenges in regenerative medicine. Nat Med. 2014;20:814-821.
25. Terzic A, Harper CM Jr, Gores GJ, Pfenning MA. Regenerative medicine blueprint. Stem Cells Dev. 2013;22(suppl 1):20-24.
26. Trainor N, Pietak A, Smith T. Rethinking clinical delivery of adult stem cell therapies. Nat Biotechnol. 2014;32:729-735.